Alcon Breaks Ground On Singapore Plant To Make Eye-care Drugs
This article was originally published in PharmAsia News
Executive Summary
Alcon, a Switzerland-based maker of eye-care products, has begun construction of its first Asian production plant in Singapore. Alcon said the plant was needed because of the company's growth in Asia, for making drugs to treat eye disorders such as glaucoma. Alcon said it expects to complete construction in 2012, when it expects to create 150 new jobs. Novartis AG, another Swiss drug maker, plans to buy a 77 percent interest in Alcon, beyond its existing 25 percent stake. (Click here for more
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.